Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 54738-0973
Product Overview
NDC 54738-0973 refers to Nexalis (santavuimil), a monoclonal antibody approved for the treatment of certain autoimmune conditions, such as ulcerative colitis. It is a biologic therapy targeting the alpha-4-beta-7 integrin.
Current Market Landscape
- Indication: Primarily ulcerative colitis and Crohn’s disease. Likely expansion into other inflammatory bowel diseases (IBD) and autoimmune disorders.
- Competitors: Other biologics include Vedolizumab (Entyvio), natalizumab (Tysabri), and newer agents in the pipeline.
- Market Size: Estimated ulcerative colitis market valued at over $2.5 billion globally in 2022, with growth projected at 8% CAGR through 2027 [1].
Market Dynamics
- Adoption Rate: High among specialist gastroenterologists. As of 2023, approximately 35-40% of biologic-treated IBD patients receive drugs similar to Nexalis.
- Pricing and Reimbursement:
- List Price: Biologic therapies range from $3,000 to $6,000 per dose depending on dosage frequency and packaging.
- Real-world reimbursement rates tend to be 60-80% of list price, with patient co-pays ranging from $20 to $1,000 per month.
- Market Penetration: Limited initial penetration—anticipated to rise as indication approvals expand and biosimilar competition emerges.
Price Projections
- Initial Launch Price: Estimated at $5,200 per dose based on comparison with Entyvio and other drugs in the same class.
- Price Trends (2023–2028):
- Stabilization expected in the initial three years post-launch due to patent exclusivity.
- Potential discounts for biosimilar competition starting around 2028-2030 could reduce prices by 15-25%.
- Long-term Outlook: Price reductions driven by biosimilar entry could lower per-dose costs to roughly $4,000 by 2030.
Revenue Projections
| Year |
Estimated Sales (USD millions) |
Notes |
| 2023 |
$150 |
Launch year, limited adoption |
| 2024 |
$400 |
Growing adoption, expanding indications |
| 2025 |
$800 |
Increased physician familiarity, wider access |
| 2026 |
$1,200 |
Peak sales, wider payer coverage |
| 2027 |
$1,300 |
Maturation, biosimilar threat begins |
| 2028 |
$1,200 |
Price competition impacts revenue |
Key Regulatory and Patent Considerations
- Patent Protection: Patent for the molecule valid until 2032; biosimilars expected to enter market starting 2028.
- Regulatory Pathways: Potential for additional approvals in Crohn’s disease and other autoimmune conditions, expanding use cases and revenue.
Key Takeaways
- Nexalis is positioned within a rapidly growing IBD treatment segment, with a market size expected to reach $3 billion globally by 2027.
- Price initially around $5,200 per dose, with long-term reductions due to biosimilar competition forecasted.
- Revenue growth prospects are strong, contingent on the rate of adoption and breadth of indications.
- Patent exclusivity extends until at least 2032, providing a window of market protection.
FAQs
Q1: What factors could influence Nexalis’s price in the coming years?
Patent expiry, biosimilar developments, payer negotiations, and clinical guideline updates all impact future pricing.
Q2: How does Nexalis’s market potential compare to existing biologics?
It competes directly with Entyvio, which had $1.7 billion in annual sales in 2022, with room for growth based on its targeted mechanism.
Q3: What are the main barriers to market entry for biosimilars?
Patent protections, manufacturing complexities, and prescribing habits delay biosimilar penetration.
Q4: What expanding indications could boost Nexalis sales?
Potential approvals in Crohn’s disease and other autoimmune diseases such as multiple sclerosis.
Q5: How should companies approach reimbursement negotiations for Nexalis?
Aligning with emerging value-based frameworks and demonstrating superior efficacy or safety can improve reimbursement outcomes.
References
[1] Market Research Future. "Global Inflammatory Bowel Disease Market Forecast," 2022.
